Holen Sie sich die Stockscreener-App
1.14
7.55%
0.08
Vorhandelsmarkt:
1.29
0.15
+13.16%
Schlusskurs vom Vortag:
$1.06
Offen:
$1.08
24-Stunden-Volumen:
847.43K
Relative Volume:
0.72
Marktkapitalisierung:
$111.21M
Einnahmen:
$1.20M
Nettoeinkommen (Verlust:
$-47.60M
KGV:
-1.4418
EPS:
-0.7907
Netto-Cashflow:
$-27.78M
1W Leistung:
-4.20%
1M Leistung:
-15.56%
6M Leistung:
+137.90%
1J Leistung:
-20.83%
1-Tages-Spanne:
$1.08
$1.15
1-Wochen-Bereich:
$1.06
$1.19
52-Wochen-Spanne:
$0.387
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Firmenname
Rani Therapeutics Holdings Inc
Sektor
Branche
Telefon
(408) 457-3700
Adresse
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
1.14 | 111.21M | 1.20M | -47.60M | -27.78M | -0.7907 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-02 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-14 | Eingeleitet | Maxim Group | Buy |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-07-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Rani Therapeutics Holdings Inc Aktie (RANI) Neueste Nachrichten
Rani Therapeutics Appoints Jesper Hoiland as Head of Strategy to Advance Corporate and Pipeline Prioritization - Bitget
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization - The Manila Times
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Drive Corporate and Pipeline Development - Quiver Quantitative
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization - GlobeNewswire Inc.
Rani Therapeutics Holdings Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
Rani Therapeutics (RANI) Expected to Announce Earnings on Monday - MarketBeat
If You Invested $1,000 in Rani Therapeutics Holdings, Inc. (RANI) - Stock Titan
US Market Recap: Will Rani Therapeutics Holdings Inc outperform during market ralliesFed Meeting & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Analyst Calls: Will Rani Therapeutics Holdings Inc outperform during market ralliesTrade Risk Assessment & Real-Time Stock Entry Alerts - baoquankhu1.vn
Volatility Watch: Can Rani Therapeutics Holdings Inc beat the S P 5002026 Review & Risk Managed Investment Entry Signals - baoquankhu1.vn
Published on: 2026-03-21 04:57:56 - baoquankhu1.vn
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Rani Therapeutics Holdings Inc (RANI) - MSN
Aug Momentum: Can Rani Therapeutics Holdings Inc navigate macro headwinds2026 Growth vs Value & AI Driven Stock Reports - baoquankhu1.vn
RANI SEC FilingsRani Therapeutics Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Rani Therapeutics Holdings Inc. (RANI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Rani Therapeutics Hldgs (RANI) Stock Analysis Report | Financials & Insights - Benzinga Japan
RANI Stock Price, Quote & Chart | RANI THERAPEUTICS HOLDINGS-A (NASDAQ:RANI) - ChartMill
US Market Wrap: Will Rani Therapeutics Holdings Inc outperform during market rallies2026 Institutional Moves & High Win Rate Trade Tips - baoquankhu1.vn
What is the next catalyst for Rani Therapeutics Holdings Inc2026 Market WrapUp & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Maxim Group Keeps Their Buy Rating on Rani Therapeutics Holdings (RANI) - The Globe and Mail
What is Rani Therapeutics Holdings Incs revenue forecastTrade Analysis Report & Low Risk Growth Stock Ideas - baoquankhu1.vn
Rani Therapeutics Holdings, Inc.Class A Common Stock (Nasdaq:RANI) Stock Quote - The Chronicle-Journal
RANI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
RANIRani Therapeutics Holdings, Inc. Latest Stock News & Market Updates - Stock Titan
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Bank Watch: What dividend growth rate does Deswell Industries Inc offerTrend Reversal & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Can Rani Therapeutics Holdings Inc. reach all time highs this year2025 Market WrapUp & Verified Momentum Watchlists - mfd.ru
Will Rani Therapeutics Holdings Inc. stock outperform growth indexesWeekly Investment Report & High Accuracy Trade Signal Alerts - mfd.ru
Published on: 2026-02-20 14:00:46 - baoquankhu1.vn
Published on: 2026-02-20 04:36:50 - baoquankhu1.vn
Rani Therapeutics (NASDAQ:RANI) Trading 1.6% HigherTime to Buy? - MarketBeat
RANI Should I Buy - Intellectia AI
Will Rani Therapeutics Holdings Inc. outperform during market rallies2025 Big Picture & High Conviction Investment Ideas - mfd.ru
Does Rani Therapeutics Holdings Inc. offer margin of safety2025 Year in Review & Safe Investment Capital Preservation Plans - mfd.ru
Investment firm reports 9.9% stake in Rani Therapeutics (RANI) - Stock Titan
Published on: 2026-02-13 18:32:35 - baoquankhu1.vn
SymBiosis Capital takes 6.5% passive stake in Rani Therapeutics (RANI) Class A - Stock Titan
Is Rani Therapeutics Holdings Inc. stock near bottom after decline2025 Year in Review & Consistent Growth Equity Picks - mfd.ru
Income Plays: What is the next catalyst for Rani Therapeutics Holdings IncWeekly Trade Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Published on: 2026-02-02 11:44:32 - baoquankhu1.vn
Insider Buyers At Rani Therapeutics Holdings Sitting On US$1.3m Profit - simplywall.st
Vanguard discloses 5.23% Rani Therapeutics (RANI) stake in Schedule 13G - Stock Titan
Rani Therapeutics promotes Alireza Javadi to chief technical officer By Investing.com - Investing.com South Africa
Rani Therapeutics Holdings, Inc. Announces Promotion of Alireza Javadi to Chief Technical Officer - marketscreener.com
Rani Therapeutics announces the promotion of Alireza Javadi, Ph.D. to chief technical officer - marketscreener.com
Rani Therapeutics Names Alireza Javadi Chief Technical Officer - Nasdaq
Rani Therapeutics promotes Alireza Javadi to chief technical officer - Investing.com
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer - The Manila Times
Finanzdaten der Rani Therapeutics Holdings Inc-Aktie (RANI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rani Therapeutics Holdings Inc-Aktie (RANI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| South Cone Investments Limited | 10% Owner |
Oct 21 '25 |
Sale |
2.77 |
4,000,000 |
11,074,000 |
2,379,194 |
| South Cone Investments Limited | 10% Owner |
Oct 20 '25 |
Sale |
2.41 |
1,923,000 |
4,637,314 |
6,379,194 |
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):